NanoImaging Services collaborates with Viva Biotech to offer an integrated CryoEM gene-to-structure workflow

NanoImaging Services, Inc., the industry provider of cryoEM services, microscope access and training, and Viva Biotech Holdings, a leading open-access and innovation-driven technology platform company, have announced a partnership agreement to develop a streamlined, cryoEM enabled gene-to-structure workflow, to ultimately accelerate medicinal chemistry analysis.

This strategic partnership will bring together NanoImaging Services’ industry-leading expertise and innovation in high-resolution structural enablement by cryoEM and Viva Biotech’s world-leading drug discovery platform to enable the management of projects from construct design through to final maps and subsequent protein supply, and analyses for medicinal chemistry cycles. This seamlessly integrated workflow will facilitate target and structure validation for companies with challenging targets in an efficient and cost-effective manner, streamlining drug discovery pipelines and ultimately reducing the time to clinic.

Giovanna Scapin, Ph.D., Chief Scientific Officer at NanoImaging Services said, “One of the strongest predictors of success in structural enablement of drug discovery targets is the purity, homogeneity, and in-depth biochemical and biophysical characterization of the reagents involved. This agreement utilizes our industry-leading expertise and innovation in high-resolution structural enablement by cryoEM, partnered with a worldwide leader in protein production and characterization. Together we aim to successfully target the most complex and challenging projects in drug discovery for our shared clients in a cost- and time-effective manner.”

“We are very excited to build the strategic cooperation with NanoImaging Services,” said Dr. Ren Delin, Executive Director and President of Viva. “NanoImaging Services, the world's top cryoEM service provider, has considerable advantages in technology and equipment. As the world's leading drug discovery platform, Viva has efficient protein purification and production capabilities, along with advanced membrane protein expression and screening technology. Our cooperation is expected to further enhance the ability of target discovery, to empower the clients to develop new drugs as soon as possible, and benefit more patients.” said Dr. Ren Delin, Executive Director and President of Viva Biotech.

By combining forces and aligning these already successful and proven workflows, target enablement and medicinal chemistry timelines can be shortened significantly. This, along with the increased success rates, can contribute to bringing down the overall investment costs and creating a more efficient workflow.

Want the latest science news straight to your inbox? Become a SelectScience member for free today>>